Pitavastatin - Palvella Therapeutics
Alternative Names: QTORIN™ pitavastatin - Palvella TherapeuticsLatest Information Update: 03 Jun 2026
At a glance
- Originator Palvella Therapeutics
- Class Alcohols; Alkenes; Antihyperlipidaemics; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Quinolines; Skin disorder therapies; Small molecules
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Skin disorders
Most Recent Events
- 27 May 2026 Palvella Therapeutics has patent protection for Pitavastatin licensed from Yale University in USA
- 31 Mar 2026 Palvella Therapeutics receives written feedback from the US FDA on the proposed phase II study design for Skin disorders
- 25 Mar 2026 Palvella Therapeutics has patent pending for Pitavastatin licensed from Yale University in USA